Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255645 · ClinicalTrials.gov registry record
G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)
A clinical trial, sponsored by AstraZeneca.
- Terminated
- Registry status
- 4,500
- Enrollment target
NCT00255645: Clinical Trial study, sponsored by AstraZeneca.
NCT00255645 is a clinical trial that was terminated before completion, run by AstraZeneca. The registered enrollment target is 4,500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00255645 was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- 4,500 participants
- Enrollment target
Study Summary
This is a long-term safety follow-up study to assess the post-treatment safety, at 12 and 24 months, in patients with type 2 diabetes after participation in the phaseII/III studies GALLANT, GALLEX and ARMOR. In addition, selected patients, including those with pre-defined laboratory or clinical findings, will have a 12-week post-treatment follow-up visit, including laboratory evaluation and adverse event recording.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,500 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-12 |
Why NCT00255645 stopped before completion
NCT00255645 is an observational study that tracks outcomes without assigning an intervention. Its 4,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00255645 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00255645 about?
NCT00255645 is a clinical study titled "G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)". This is a long-term safety follow-up study to assess the post-treatment safety, at 12 and 24 months, in patients with type 2 diabetes after participation in the phaseII/III studies GALLANT, GALLEX and ARMOR. In addition, selected patients, including those with pre-defined laboratory or clinical find...
What is the current status of trial NCT00255645?
This trial is currently terminated. The enrollment target is 4,500 participants. The study started on 2005-09. Estimated completion is 2006-12.
Who is sponsoring clinical trial NCT00255645?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- NCT07207564 · 4,500 participants
Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia